Skip to main content

Advertisement

SpringerLink
Log in

Management of infections caused by Candida glabrata

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Candida glabrata infections undoubtedly have become more frequent, and are now common. They appear to be the consequence of widespread and often indiscriminate use of azoles, especially fluconazole. This species constitutes the Achilles heel of all available azoles, including newer ones in the pipeline. Even when amphotericin B is used, higher dosages are now required. Little is known about the epidemiology of and risk factors for this troublesome species; even less about its virulence factors. However, studying the resistance mechanisms of this haploid organism may provide answers in developing new fungicidal agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Fidel PL Jr, Vazquez JA, Sobel JD: Candida glabrata: Review of epidemiology, pathogenesis and clinical disease with comparison to C. albicans. Clin Microbiol Rev 1999, 12:80–96. This is a detailed description of the biology, epidemiology, clinical manifestations and treatment of C. glabrata.

    PubMed  Google Scholar 

  2. Komshian SV, Uwaydah AK, Sobel JD: Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989, 11:379–390.

    PubMed  CAS  Google Scholar 

  3. Kao AS, Brandt ME, Pruitt WR, et al.: The epidemiology of candidemia in two United States cities: results of a population — based active surveillance. Clin Infect Dis 1999, 29:1164–1170.

    Article  PubMed  CAS  Google Scholar 

  4. Pfaller MA, Jones RN, Doern GV, et al.: International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. Diag Microbiol Infect Dis 1999, 35:19–25.

    Article  CAS  Google Scholar 

  5. Pfaller MA, Jones RN, Doern GV, et al.: Bloodstream infections due to Candida species: SENTRY Antimicrobial Surveillance program in North America and Latin America, 1997–1998. Antimicrob Agents Chemother 2000, 44:747–751.

    Article  PubMed  CAS  Google Scholar 

  6. Viscoli C, Girmenia C, Marinus A, et al.: Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (FORTC). Clin Infect Dis 1999, 28:1071–1079.

    PubMed  CAS  Google Scholar 

  7. Nguyen MH, Peacock JE, Morris AJ, et al.: The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996, 100:617–623.

    Article  PubMed  CAS  Google Scholar 

  8. Ramgel-Grausto MS, Wiblin T, Blumberg HM, et al.: National epidemiology of mycoses survey (NEMIS): variations in rates of blood stream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999, 29:253–258. This major national epidemiologic study reports the variations in bloodstream infections due to Candida species that specifically targets both adult and neonatal patients in intensive care units.

    Google Scholar 

  9. Abi-Said D, Anaissie E, Uzun O, et al.: The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997, 24:1122–1128.

    PubMed  CAS  Google Scholar 

  10. Voso A, Kluytmans JA, Koeleman JG, et al.: Occurrence of yeast bloodstream infections between 1987 and 1993 in five Dutch University Hospitals. Eur J Clin Microbiol Infect Dis 1996, 15:909–917.

    Article  Google Scholar 

  11. Wingard JR, Metz WG, Rinaldi MG, et al.: Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993, 37:1847–1849.

    PubMed  CAS  Google Scholar 

  12. Edmond MB, McClish DK, Pfaller MA, et al.: Nosocomial bloodstream infections in United States hospitals: a three year study. Clin Infect Dis 1999, 29:239–244.

    PubMed  CAS  Google Scholar 

  13. Pulimood S, Alangaden G, Chandrasekar PH: Changing epidemiology at a tertiary care institution [abstract]. In Proceedings of the International Symposium on Infections in the Immunocompromised Host. Davos, Switzerland, 1998:093.

  14. Gumbo T, Isada CM, Hall G, et al.: Candida glabrata fungemia: Clinical features of 139 patients. Medicine 1999, 78:220–227. This retrospective review of the largest collection of patients with fungemia due to C. glabrata features multiple case reports and highlights the spectrum of disease as well as management difficulties that inevitably arise in clinical practice.

    Article  PubMed  CAS  Google Scholar 

  15. Kauffman CA, Vazquez JA, Sobel JD, et al.: Prospective multicenter surveillance study of funguria in hospitalized patients. Clin Infect Dis 2000, 20:14–18. This prospective multicenter surveillance epidemiology study of 1000 cases of funguria in hospitalized patients describes risk factors for funguria, aspects of natural history, and effects of catheter removal.

    Article  Google Scholar 

  16. Price MF, Larocco MT, Gentry LO: Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother 1994, 38:1422–1427.

    PubMed  CAS  Google Scholar 

  17. Sobel JD: Vulvovaginitis due to Candida glabrata. An emerging problem. Mycoses 1998, 41(Suppl 2):18–22.

    Article  PubMed  Google Scholar 

  18. Trupl J, Kunova A, Oravcova E, et al.: Resistance pattern of 2816 isolates isolated from 17631 blood cultures and etiology of bacteremia and fungemia in a single cancer institution. Acta Oncol 1997, 26:643–649.

    Google Scholar 

  19. Rex JH, Pfaller MA, Barry AL, et al.: Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrob Agents Chemother 1995, 39:40–44.

    PubMed  CAS  Google Scholar 

  20. Rex JH, Walsh TJ, Sobel JD, et al.: Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000, 30:662–678. In this article, an expert panel recommends evidence-based guidelines about how and when to treat superficial and deep Candida infections, summarizing the evidence to support the recommendations.

    Article  PubMed  CAS  Google Scholar 

  21. Rex JH, Pfaller MA, Galgiani JN, et al.: Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro — in vivo correlation data for fluconazole, itraconazole and Candida infections. Clin Infect Dis 1997, 24:235–247.

    PubMed  CAS  Google Scholar 

  22. Phillips P, Shafran S, Garber G, et al.: Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 1997, 16:337–345.

    Article  PubMed  CAS  Google Scholar 

  23. Winston DJ, Hathorn JW, Schuster MG, et al.: A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000, 108:282–289. This is the first multicenter, randomized trial of parenteral fluconazole versus amphotericin B for empiric therapy of fever in neutropenic cancer patients. The authors concluded that, in selected patients, fluconazole therapy is as effective as amphotericin B, despite poor activity against Aspergillus species.

    Article  PubMed  CAS  Google Scholar 

  24. Anaissie EJ, Varlivarian SE, Abi-Said D, et al.: Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 1996, 101:170–176.

    Article  PubMed  CAS  Google Scholar 

  25. Rex JH, Bennett JE, Sugar AM, et al.: A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994, 331:1325–1330.

    Article  PubMed  CAS  Google Scholar 

  26. Edwards JE, Bodey GP, Bowden RA, et al.: International conference for development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997, 25:43–59.

    PubMed  Google Scholar 

  27. Kauffman CA, Zarins LT: Colorimetric method for susceptibility testing of voriconazole and other triazoles against Candida species. Mycoses 1999, 42:539–542.

    Article  PubMed  CAS  Google Scholar 

  28. Sanglard D, Ischer F, Calabrese D, et al.: The ATP binding cassette transporter gene Cg CDR1 for Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob Agents Chemother 1999, 43:2753–2765.

    PubMed  CAS  Google Scholar 

  29. Phillips P, Zemcov J, Mahmood W: Intraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. AIDS 1996, 10:1369–1376.

    Article  PubMed  CAS  Google Scholar 

  30. Cauwenbergh G: Vaginal candidiasis: evolving trends in the incidence and treatment of non-Candida albicans infections. Curr Probl Obstet Gynecol Fertil 1990, 8:241–245.

    Google Scholar 

  31. Sobel JD: One versus two doses of fluconazole for complicated Candida vaginitis. (Submitted for publication).

  32. Sobel JD, Chaim W: Treatment of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy. Clin Infect Dis 1997, 24:649–652.

    PubMed  CAS  Google Scholar 

  33. Sobel JD, Kauffman CA, McKinsey D, et al.: Candiduria: A randomized, double-blind study of treatment with fluconazole and placebo. Clin Infect Dis 2000, 30:19–24. This placebo controlled prospective randomized study of asymptomatic candiduria in hospitalized patients yielded much of clinical relevance. The authors quantified the beneficial effects of Foley catheter change and removal in candiduria. They also found fluconazole therapy to be disappointing due to candiduria relapse fairly soon after cessation of therapy.

    Article  PubMed  CAS  Google Scholar 

  34. Harris AD, Castro J, Sheppard DC, et al.: Risk factors for nosocomial candiduria due to Candida glabrata and Candida albicans. Clin Infect Dis 1999, 29:926–928.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Wayne State University School of Medicine and Harper Hospital, 4 Brush, Room 4811, 3990 John R, 48201, Detroit, MI, USA

    Jack D. Sobel MD

Authors
  1. Jack D. Sobel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sobel, J.D. Management of infections caused by Candida glabrata . Curr Infect Dis Rep 2, 424–428 (2000). https://doi.org/10.1007/s11908-000-0069-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-000-0069-x

Keywords

Search

Navigation